NASDAQ:ROIV Roivant Sciences Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $4.51 +0.09 (+2.04%) (As of 07/5/2022 01:38 PM ET) Add Compare Share Today's Range$4.19▼$4.5850-Day Range$2.81▼$4.7952-Week Range$2.52▼$16.76Volume24,199 shsAverage Volume1.01 million shsMarket Capitalization$3.12 billionP/E RatioN/ADividend YieldN/APrice Target$12.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Roivant Sciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside167.3% Upside$12.00 Price TargetShort InterestBearish1.81% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.12Based on 18 Articles This WeekInsider TradingSelling Shares$1.29 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.36) to ($1.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.97 out of 5 starsMedical Sector534th out of 1,428 stocksPharmaceutical Preparations Industry254th out of 680 stocks 3.5 Analyst's Opinion Consensus RatingRoivant Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Roivant Sciences has a forecasted upside of 167.3% from its current price of $4.49.Amount of Analyst CoverageRoivant Sciences has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.81% of the float of Roivant Sciences has been sold short.Short Interest Ratio / Days to CoverRoivant Sciences has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Roivant Sciences has recently increased by 65.28%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRoivant Sciences does not currently pay a dividend.Dividend GrowthRoivant Sciences does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ROIV. Previous Next 2.3 News and Social Media Coverage News SentimentRoivant Sciences has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Roivant Sciences this week, compared to 2 articles on an average week.Search Interest12 people have searched for ROIV on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Roivant Sciences insiders have sold 729.97% more of their company's stock than they have bought. Specifically, they have bought $154,980.00 in company stock and sold $1,286,291.00 in company stock.Percentage Held by Institutions61.49% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Roivant Sciences are expected to grow in the coming year, from ($1.36) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Roivant Sciences is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Roivant Sciences is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRoivant Sciences has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ROIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address About Roivant Sciences (NASDAQ:ROIV) StockRoivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.Read More ROIV Stock News HeadlinesJuly 5, 2022 | americanbankingnews.comQ2 2023 EPS Estimates for Roivant Sciences Ltd. Lowered by Analyst (NASDAQ:ROIV)July 1, 2022 | americanbankingnews.comRoivant Sciences (NASDAQ:ROIV) Receives "Buy" Rating from HC WainwrightJuly 5, 2022 | Investing Daily (Ad)27 U.S. Cities Where Stocks Yield 26% a YearWhat’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. July 1, 2022 | americanbankingnews.comRoivant Sciences (NASDAQ:ROIV) PT Raised to $7.00June 30, 2022 | finance.yahoo.comRoivant Sciences Ltd. (NASDAQ:ROIV) Analysts Are Cutting Their Estimates: Here's What You Need To KnowJune 30, 2022 | americanbankingnews.comInsider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 16,402 Shares of StockJune 29, 2022 | markets.businessinsider.comAnalyst Ratings for Roivant SciencesJune 28, 2022 | seekingalpha.comRoivant axes gene therapy, dermatology and excessive sweating candidates from developmentJuly 5, 2022 | Investing Daily (Ad)27 U.S. Cities Where Stocks Yield 26% a YearWhat’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. June 28, 2022 | seekingalpha.comRoivant Sciences teams up with Pfizer to launch PriovantJune 28, 2022 | finance.yahoo.comRoivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business UpdateJune 28, 2022 | finance.yahoo.comRoivant, Pfizer unveil Priovant Therapeutics focused on autoimmune disease treatments, Roivant stock surgesJune 28, 2022 | americanbankingnews.comRoivant Sciences Ltd. (NASDAQ:ROIV) CEO Matthew Gline Sells 19,855 SharesJune 23, 2022 | americanbankingnews.comRoivant Sciences (NASDAQ:ROIV) Trading Down 2.3%June 23, 2022 | americanbankingnews.comRoivant Sciences (NASDAQ:ROIV) Trading Down 2.3%June 19, 2022 | americanbankingnews.comRoivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Recommendation of "Buy" from AnalystsJune 15, 2022 | finance.yahoo.comRoivant Sciences to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 on Tuesday, June 28, 2022June 10, 2022 | americanbankingnews.comEquities Analysts Set Expectations for Roivant Sciences Ltd.'s FY2023 Earnings (NASDAQ:ROIV)May 24, 2022 | marketwatch.comRoivant Shares Rise 6% on Vtama's FDA ApprovalMay 24, 2022 | markets.businessinsider.comDermavant Sciences Says FDA Approves VTAMA Cream, 1% For Plaque Psoriasis In AdultsMay 24, 2022 | seekingalpha.comRoivant gets FDA approval for plaque psoriasis therapy Vtama creamMay 24, 2022 | finance.yahoo.comFDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 YearsMay 9, 2022 | finance.yahoo.comWhat Type Of Shareholders Own The Most Number of Roivant Sciences Ltd. (NASDAQ:ROIV) Shares?April 29, 2022 | benzinga.comCantor Fitzgerald Initiates Coverage On Roivant Sciences with Overweight Rating, Announces Price Target of $15April 20, 2022 | finance.yahoo.comVantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein DegradersApril 15, 2022 | seekingalpha.comMyovant: Endometriosis Setback Hints At Deeper Issues Around Pfizer PartnershipApril 8, 2022 | investing.comRoivant Sciences Ltd (ROIV)See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ROIV CUSIPN/A CIK1635088 Webroivant.com Phone44 4412 955 950FaxN/AEmployees620Year FoundedN/ACompany Calendar Today7/05/2022Fiscal Year End3/31/2023Price Target and Rating Average Stock Price Forecast$12.00 High Stock Price Forecast$15.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+173.5%Consensus RatingBuy Rating Score (0-4)3 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-845,260,000.00 Net Margins-1,528.89% Pretax Margin-1,670.85% Return on Equity-55.50% Return on Assets-43.99% Debt Debt-to-Equity Ratio0.10 Current Ratio11.64 Quick Ratio11.64 Sales & Book Value Annual Sales$55.29 million Price / Sales56.45 Cash FlowN/A Price / Cash FlowN/A Book Value$2.95 per share Price / Book1.53Miscellaneous Outstanding Shares692,070,000Free FloatN/AMarket Cap$3.12 billion OptionableNot Optionable Beta1.58 Roivant Sciences Frequently Asked Questions Should I buy or sell Roivant Sciences stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Roivant Sciences stock. View analyst ratings for Roivant Sciences or view top-rated stocks. What is Roivant Sciences' stock price forecast for 2022? 8 brokers have issued 1 year price objectives for Roivant Sciences' stock. Their ROIV stock forecasts range from $7.00 to $15.00. On average, they expect Roivant Sciences' share price to reach $12.00 in the next twelve months. This suggests a possible upside of 167.3% from the stock's current price. View analysts' price targets for Roivant Sciences or view top-rated stocks among Wall Street analysts. How has Roivant Sciences' stock price performed in 2022? Roivant Sciences' stock was trading at $10.08 at the start of the year. Since then, ROIV stock has decreased by 55.5% and is now trading at $4.49. View the best growth stocks for 2022 here. Who are Roivant Sciences' key executives? Roivant Sciences' management team includes the following people: Mr. Matthew Gline, CEO & Director (Age 38, Pay $813.55k)Dr. Eric Venker M.D., Pharm.D., Pres & COO (Age 35, Pay $813.55k)Dr. Mayukh Sukhatme M.D., Pres & Chief Investment Officer (Age 46)Mr. Richard Pulik, Chief Financial Officer (Age 43)Ms. Rakhi Kumar, Chief Accounting Officer (Age 42)Mr. Josh Chen, Gen. CounselMs. Marianne L. Romeo, Head of Global Transactions & Risk Management (Age 54)Dr. Woody Sherman Ph.D., Chief Computational ScientistMr. Alex Gasner, Exec. VP of Roivant HealthDr. Matt Maisak, Chief Operating Officer of Roivant Platforms Who are some of Roivant Sciences' key competitors? Some companies that are related to Roivant Sciences include United Therapeutics (UTHR), Biohaven Pharmaceutical (BHVN), Jazz Pharmaceuticals (JAZZ), Elanco Animal Health (ELAN), Dr. Reddy's Laboratories (RDY), Legend Biotech (LEGN), Organon & Co. (OGN), Teva Pharmaceutical Industries (TEVA), Grifols (GRFS), Maravai LifeSciences (MRVI), Sarepta Therapeutics (SRPT), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Ionis Pharmaceuticals (IONS) and Intra-Cellular Therapies (ITCI). View all of ROIV's competitors. What is Roivant Sciences' stock symbol? Roivant Sciences trades on the NASDAQ under the ticker symbol "ROIV." How do I buy shares of Roivant Sciences? Shares of ROIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Roivant Sciences' stock price today? One share of ROIV stock can currently be purchased for approximately $4.49. How much money does Roivant Sciences make? Roivant Sciences (NASDAQ:ROIV) has a market capitalization of $3.11 billion and generates $55.29 million in revenue each year. The company earns $-845,260,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. How many employees does Roivant Sciences have? Roivant Sciences employs 620 workers across the globe. How can I contact Roivant Sciences? Roivant Sciences' mailing address is Clarendon House, 2 Church Street, Hamilton Parish HM 11. The official website for Roivant Sciences is roivant.com. The company can be reached via phone at 44 4412 955 950. This page (NASDAQ:ROIV) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
